jain.com
The Analysis · Companies · People · Methodology

Warrant issuance to lenders

Company: TeraWulf

This claim was marked delayed on September 15, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
financing
Statement date
2022-08-03
Promised by
2022-09-29
Promised amount
5787732.0 shares
Current status
delayed

The claim, verbatim

Issued warrants for 5,787,732 shares with $0.01 exercise price, exercisable beginning September 29, 2022 through December 31, 2025

Source (primary)

TeraWulf S-3/A filed 2022-08-04 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗

Quote: “On July 1, 2022, the Company entered into the Warrant Agreement to issue Warrants to the lenders under its amendment to the Loan, Guaranty and Security Agreement...The Warrants are exercisable beginning on September 29, 2022 and will expire on December 31, 2025”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms TeraWulf S-3/A filed 2022-08-04

Quote: “On July 1, 2022, the Company entered into the Warrant Agreement to issue Warrants to the lenders under its amendment to the Loan, Guaranty and Security Agreement...The Warrants are exercisable beginning on September 29, 2022 and will expire on December 31, 2025”

View cached copy (2026-09-13)Live source ↗

Record of changes

September 14, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 15, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.